Climb Bio
Climb Bio

Financials • Climb Bio

CLYM

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

12/2023
1 financial
12/2023
Year
0
-40
-35
L
108
L
-106
-
-33
0
1
-33
L

To see all financials—including updated, you must be Premium.